The Dow Jones Industrial Average posted its worst January performance ever and worst February since the Great Depression, and then in March it did an about face and generated one of its biggest one-month gains in years. The IPO market still remained closed to biotechs, but on the financing side the numbers actually looked pretty good in the first quarter as the industry posted a 47 percent increase over the same period a year ago. With Roche’s purchase of Genentech, the collective market cap for the biotech sector sunk below the $300 billion mark, but the deal also fuels the discussion about whether it even has meaning anymore to talk about a pharmaceutical industry and a biotechnology industry that are separate and distinct from each other. We spoke to Peter Winter, editor of The Burrill Report about the first quarter numbers, where the money went, and what it all means.
Glimmers of Hope Fragile economy shows signs of a possible recovery during a quiet week for life sciences deal-makers
Deadly Disconnect Hospitals with higher self-reported safety scores don’t have a substantially lower rate of patient deaths.
Double Whammy The number of Americans with at least one chronic disease is rising, as is their problems with paying for care.
Biotech Survival Guide Here are some key tips on how to stay the course during the global economic crisis.
Let’s Make a Steal Global dealmaking among biotechs will remain active in 2009, but M&A; and licensing deal values could decline as buyers seek out bargains.
Subscribe to one of our feeds
Print
The Dow Jones Industrial Average posted its worst January performance ever and worst February since the Great Depression, and then in March it did an about face and generated one of its biggest one-month gains in years. The IPO market still remained closed to biotechs, but on the financing side the numbers actually looked pretty good in the first quarter as the industry posted a 47 percent increase over the same period a year ago. With Roche’s purchase of Genentech, the collective market cap for the biotech sector sunk below the $300 billion mark, but the deal also fuels the discussion about whether it even has meaning anymore to talk about a pharmaceutical industry and a biotechnology industry that are separate and distinct from each other. We spoke to Peter Winter, editor of The Burrill Report about the first quarter numbers, where the money went, and what it all means. 